Morningstar

SpringWorks Therapeutics Inc Ordinary Shares SWTX

Morningstar Rating

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

GlobeNewswire Aug 28, 2024 10:30am
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire Aug 7, 2024 10:30am
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

GlobeNewswire Jul 29, 2024 10:30am
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

GlobeNewswire Jul 23, 2024 11:00am
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

PR Newswire Jul 2, 2024 4:49pm
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

GlobeNewswire Jul 1, 2024 10:30am
SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors

MarketWatch Nov 28, 2023 4:06pm
SpringWorks Shares Rise on FDA Approval for Tumor Treatment

Global News Select Nov 28, 2023 12:38pm
SpringWorks Gets FDA Approval for Desmoid Tumor Treatment

Global News Select Nov 27, 2023 11:31pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.